Savara Inc. (NASDAQ:SVRA) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Savara Inc. (NASDAQ:SVRA - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five research firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $5.60.

A number of brokerages recently weighed in on SVRA. Guggenheim reaffirmed a "buy" rating and issued a $8.00 price target (down from $9.00) on shares of Savara in a research note on Wednesday, May 28th. Evercore ISI decreased their price target on shares of Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a research note on Wednesday, May 28th. Wells Fargo & Company decreased their price target on shares of Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 28th. Finally, HC Wainwright lowered shares of Savara from a "buy" rating to a "neutral" rating and decreased their price target for the company from $6.00 to $2.00 in a research note on Thursday, May 29th.

Savara Price Performance

Shares of NASDAQ:SVRA remained flat at $2.21 during trading on Wednesday. The stock had a trading volume of 2,317,818 shares, compared to its average volume of 1,269,474. Savara has a 52-week low of $1.89 and a 52-week high of $5.11. The company has a current ratio of 14.91, a quick ratio of 14.91 and a debt-to-equity ratio of 0.20. The stock has a market cap of $381.98 million, a price-to-earnings ratio of -4.60 and a beta of 0.32. The stock has a fifty day simple moving average of $2.68 and a 200-day simple moving average of $2.79.

Savara (NASDAQ:SVRA - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, meeting analysts' consensus estimates of ($0.12). On average, equities research analysts forecast that Savara will post -0.45 EPS for the current year.

Insiders Place Their Bets

In other Savara news, Director Richard J. Hawkins bought 48,225 shares of the firm's stock in a transaction on Friday, June 20th. The shares were acquired at an average cost of $2.04 per share, with a total value of $98,379.00. Following the purchase, the director now directly owns 115,466 shares of the company's stock, valued at $235,550.64. This trade represents a 71.72% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 5.33% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Rhumbline Advisers raised its position in shares of Savara by 8.6% during the 1st quarter. Rhumbline Advisers now owns 153,542 shares of the company's stock valued at $425,000 after buying an additional 12,117 shares during the period. Exome Asset Management LLC raised its position in shares of Savara by 19.5% during the 1st quarter. Exome Asset Management LLC now owns 836,397 shares of the company's stock valued at $2,317,000 after buying an additional 136,699 shares during the period. Bain Capital Life Sciences Investors LLC raised its position in shares of Savara by 20.8% during the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 17,600,621 shares of the company's stock valued at $48,754,000 after buying an additional 3,035,164 shares during the period. ADAR1 Capital Management LLC raised its position in shares of Savara by 37.6% during the 1st quarter. ADAR1 Capital Management LLC now owns 1,360,291 shares of the company's stock valued at $3,768,000 after buying an additional 371,823 shares during the period. Finally, Vestal Point Capital LP raised its position in shares of Savara by 2.1% during the 1st quarter. Vestal Point Capital LP now owns 11,000,000 shares of the company's stock valued at $30,470,000 after buying an additional 225,000 shares during the period. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.